Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures - read this article along with other careers information, tips and advice on BioSpace
Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces Cooperation Agreement With HEALIOS K.K.
February 16, 2021 GMT
CLEVELAND (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’s largest shareholder and one of its commercial partners, and Dr. Hardy TS Kagimoto, a member of the Company’s Board and the Chairman and Chief Executive Officer of Healios. The cooperation agreement is intended to reaffirm the mutual commitment to collaborative development of MultiStem in Japan.
The Cleveland-based developer of the MultiStem cell therapy announced Tuesday morning, Feb. 16, that Van Bokkelen has stepped down from the roles effective immediately. Van Bokkelen co-founded Athersys in 1995. Athersys said its board of directors has appointed William (B.J.) Lehmann, the company's president and chief operating officer, as interim CEO. The board 'intends to identify and select a CEO who can guide Athersys in the commercial stage,' the company said.